Incyte ((INCY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Incyte Corporation is currently conducting a Phase 1 clinical study titled A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors. The study aims to evaluate the safety, tolerability, and dose-limiting toxicities of INCA33890, while determining the maximum tolerated dose and/or recommended dose for expansion in patients with advanced or metastatic solid tumors.
The intervention being tested is INCA33890, a drug administered alone or in combination with other treatments like bevacizumab, FOLFIRI, FOLFOX, and cetuximab. The purpose is to assess its effectiveness in treating solid tumors.
This interventional study is non-randomized and follows a sequential intervention model without masking, focusing primarily on treatment. The study is designed to explore different dosing strategies to optimize therapeutic outcomes.
The study began on April 14, 2023, with an estimated primary completion date yet to be announced. The most recent update was submitted on August 28, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
This study update could influence Incyte’s stock performance and investor sentiment by showcasing the company’s ongoing commitment to developing innovative cancer treatments. The results could also impact the competitive landscape in oncology, particularly if INCA33890 proves effective.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.